Early treatment with intravenous tissue plasminogen activator (IV tPA) (< 4.5 h from symptom onset) increases the proportion of patients who survive with a favorable outcome after ischemic stroke [1]. Though treatment is associated with better outcomes, the most feared complication is hemorrhagic transformation (HT), or bleeding into the area of ischemia when the tissue is reperfused. The gene discussed is PLAT; the disease is hematocrit.